Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA239-0008  |   NCT03785249

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Contact us for help
clinical.trials@bms.com

Summary

  • Phase 1/Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • 221
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
    1. Unresectable or metastatic disease
      1. Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
        1. Adequate organ function

          Exclusion Criteria

          Exclusion Criteria Icon
          :
          • History of intestinal disease or major gastric surgery or inability to swallow oral medications
            1. Other active cancer
              Additional Information *

              Treatment Options

              Study Arms

              ASSIGNED INTERVENTION

              Study Arms

              Experimental: Phase 1 Dose Exploration

              ASSIGNED INTERVENTION
              • Drug: MRTX849

              Study Arms

              Experimental: Phase 1b Expansion

              ASSIGNED INTERVENTION
              • Drug: MRTX849

              Study Arms

              Experimental: Phase 2

              ASSIGNED INTERVENTION
              • Drug: MRTX849

              Study Arms

              Experimental: Phase 2 Combination with Cetuximab

              ASSIGNED INTERVENTION
              • Drug: MRTX849, Cetuximab

              Study Arms

              Experimental: Pilot Phase 1b Combination with Afatinib

              ASSIGNED INTERVENTION
              • Drug: MRTX849, Afatinib

              Study Arms

              Experimental: Pilot Phase 1b Combination with Cetuximab

              ASSIGNED INTERVENTION
              • Drug: MRTX849, Cetuximab

              Study Arms

              Experimental: Pilot Phase 1b Combination with Cetuximab in NSCLC

              ASSIGNED INTERVENTION
              • Drug: MRTX849, Cetuximab

              Study Arms

              Experimental: Pilot Phase 1b Combination with Cetuximab in PDAC

              ASSIGNED INTERVENTION
              • Drug: MRTX849, Cetuximab

              Study Arms

              Experimental: Pilot Phase 1b Combination with Pembrolizumab

              ASSIGNED INTERVENTION
              • Drug: MRTX849, Pembrolizumab
              Take the first step to see if you Match to a Clinical Trial – Check if you qualify
              Check if you qualify
              Answer some questions about Your health to see if you may match to this trial
              Match to a Trial
              If you are a match, click on the study to see the list of study site locations
              Select a Study Site Location
              Select a study site location that is convenient for you
              Register
              Provide your contact details for the study site to connect with you.

              Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you